Nikolaos Neokleous

Dr. Nikolaos Neokleous


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2011 in Haematologica
Verified
Journal Article
Closed access
PDF file
ASA. Sideri
A. Sideri
NNNikolaos Neokleous
Nikolaos Neokleous
PGP. B. De La Grange
P. B. De La Grange
BGB. Guerton
B. Guerton
MKM.-C. Le Bousse Kerdilles
M.-C. Le Bousse Kerdilles
EGE. Gluckman
E. Gluckman
Umbilical cord blood transplantation has been increasingly used over the past years for both malignant and non-malignant hematologic and other diseases as an alternative to mismatched-related or matched-unrelated bone marrow or peripheral blood hematopoietic stem cell transplantation. A disadvantage of cord blood is its low cell content which limits cord blood transplantation to generally low weight recipients, such as children. Various alternatives have been used to overcome this limitation, including co-infusion of two partially HLA-matched cord blood units. According to Eurocord Registry data, this strategy has been applied in approximately 993 adult patients with hematologic diseases since the first double umbilical cord blood transplantation in 1999. In fact, since 2005, the number of adult patients receiving double umbilical cord blood transplantation has surpassed the number of adults transplanted with single cord blood units. The engraftment rate is comparable for both single and double umbilical cord blood transplantation, although the latter is accompanied by a higher incidence of grade II acute graft-versus-host disease and lower leukemia relapse for patients in first complete remission. In the majority of patients undergoing double umbilical cord blood transplantation, transient chimerism, due to the presence of cells from both donor units early post transplant, is replaced by sustained dominance of one unit from which long-term hematopoiesis is derived. Although the biology and the factors that determine unit dominance have not been clarified, the implication of immune-mediated mechanisms has been reported. Preliminary data have demonstrated the safety of double umbilical cord blood transplantation. Ongoing clinical trials and prolonged follow up of the patients will clarify the immunology and determine the efficacy of this approach. We present here a brief overview of the clinical experience on double umbilical cord blood transplantation and its underlying biology.

30 August 2012 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
VEVlachaki Efthimia
Vlachaki Efthimia
NNNikolaos Neokleous
Nikolaos Neokleous
AAAlexandra Agapidou
Alexandra Agapidou
MEMarina Economou
Marina Economou
EVEvaggelia Vetsiou
Evaggelia Vetsiou
VPVasilios Perifanis
Vasilios Perifanis

1 October 2014 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
EVEFTHYMIA VLACHAKI
EFTHYMIA VLACHAKI
AAAleka Agapidou
Aleka Agapidou
NNNikolaos Neokleous
Nikolaos Neokleous
DADespoina Adamidou
Despoina Adamidou
EVEvaggelia Vetsiou
Evaggelia Vetsiou
PBPanagiota Boura
Panagiota Boura

28 December 2011 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
EVE. Vlachaki
E. Vlachaki
AKA. Kalogeridis
A. Kalogeridis
NNNikolaos Neokleous
Nikolaos Neokleous
VPVasilios Perifanis
Vasilios Perifanis
FKF. Klonizakis
F. Klonizakis
IKI. Klonizakis
I. Klonizakis

1 January 2011 in Hematology Reports
Verified
Journal Article
Open access
NNNikolaos Neokleous
Nikolaos Neokleous
ASAnastasia Sideri
Anastasia Sideri
CPCorina Peste-Tsilimidos
Corina Peste-Tsilimidos
Over the last two decades umbilical cord blood (UCB) transplantation (UCBT) is increasingly used for a variety of malignant and benign hematological and other diseases. The main factor that limits the use of UCB to low weight recipients, mainly children and adolescents, is its low progenitor cell content. Various alternatives have been exploited to overcome this difficulty, including the transplantation of two UCB units (double umbilical cord blood transplantation, dUCBT). Following dUCBT, donor(s) hematopoietic stem cells (HSC) can be detected in the peripheral blood of the recipient as soon as 14 days post-transplantation. Sustained engraftment of HSC from one or both donors can be observed- dominance or mixed chimerism respectively, although single donor unit dominance has been observed in over 85% of patients. The underlying biology, which accounts for the interactions both between the two infused UCB units- cooperative or competitive, and with the recipient’s immune system, has not been elucidated.

1 December 2021 in Thrombosis Update
Verified
Journal Article
Open access
VPVasilios Perifanis
Vasilios Perifanis
NNNikolaos Neokleous
Nikolaos Neokleous
Dimitrios A. TsakirisDimitrios A. Tsakiris
Dimitrios A. Tsakiris